Skip to main navigation Skip to search Skip to main content

Caveolin-1 and prostate cancer progression

  • Michael R. Freeman
  • , Wei Yang
  • , Dolores Di Vizio
  • Boston Children's Hospital
  • Harvard University

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

36 Scopus citations

Abstract

Caveolin-1 was identified in the 1990s as a marker of aggressive prostate cancer. The caveolin-1 protein localizes to vesicular structures called caveolae and has been shown to bind and regulate many signaling proteins involved in oncogenesis. Caveolin-1 also has lipid binding properties and mediates aspects of cholesterol and fatty acid metabolism and can elicit biological responses in a paracrine manner when secreted. Caveolin-1 is also present in the serum of prostate cancer patients and circulating levels correlate with extent of disease. Current evidence indicates that increased expression of caveolin-1 in prostate adenocarcinoma cells and commensurate downregulation of the protein in prostate stroma, mediate progression to the castration-resistant phase of prostate cancer through diverse pathways. This chapter summarizes the current state of our understanding of the cellular and physiologic mechanisms in which caveolin-1 participates in the evolution of prostate cancer cell phenotypes.

Original languageEnglish
Title of host publicationCaveolins and Caveolae
Subtitle of host publicationRoles in Signaling and Disease Mechanisms
Pages95-110
Number of pages16
DOIs
StatePublished - 2012

Publication series

NameAdvances in Experimental Medicine and Biology
Volume729
ISSN (Print)0065-2598

Fingerprint

Dive into the research topics of 'Caveolin-1 and prostate cancer progression'. Together they form a unique fingerprint.

Cite this